Treace Medical Concepts (TMCI) Cash from Financing Activities (2020 - 2026)
Treace Medical Concepts (TMCI) posted Cash from Financing Activities of -$588000.0 for Q1 2026, down 142.55% on a QoQ basis from $1.4 million in Q4 2025, and down 108.51% year-over-year from $6.9 million in Q1 2025.
Treace Medical Concepts (TMCI) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Treace Medical Concepts' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$588000.0 for Q1 2026.
- Quarterly Cash from Financing Activities fell 108.51% year-over-year to -$588000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (up 2711.11% YoY) and the FY2025 annual result came in at $2.1 million, up 1198.12% from the prior year.
- Cash from Financing Activities was -$588000.0 for Q1 2026 at Treace Medical Concepts, down from $1.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $107.9 million in Q1 2023 and bottomed at -$588000.0 in Q1 2026.
- A 5-year average of $7.8 million and a median of $297000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities soared 7762.9% — and 2025, when it tumbled 225.0%.
- Treace Medical Concepts' Cash from Financing Activities stood at $297000.0 in 2022, then tumbled by 44.44% to $165000.0 in 2023, then slumped by 84.24% to $26000.0 in 2024, then jumped by 5215.38% to $1.4 million in 2025, then plunged by 142.55% to -$588000.0 in 2026.
- Business Quant data shows TMCI's Cash from Financing Activities at -$588000.0 in Q1 2026, $1.4 million in Q4 2025, and -$10000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Treace Medical Concepts | 261.60 Mn | 209.75 Mn | 37.41 Mn | -588,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -588,000.00 |
| Mar 31, 2026 | -588,000.00 |
| Dec 31, 2025 | 1.38 Mn |
| Dec 31, 2025 | 1.38 Mn |
| Sep 30, 2025 | -10,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Jun 30, 2025 | 987,000.00 |
| Jun 30, 2025 | 987,000.00 |
| Mar 31, 2025 | -282,000.00 |
| Mar 31, 2025 | -282,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Jun 30, 2024 | 311,000.00 |
| Jun 30, 2024 | 311,000.00 |
| Mar 31, 2024 | -185,000.00 |
| Mar 31, 2024 | -185,000.00 |
| Dec 31, 2023 | 165,000.00 |
| Dec 31, 2023 | 165,000.00 |